key: cord-1024967-0lvv7knv
authors: Lofgren, Sarah M; Okafor, Elizabeth C; Colette, Alanna A; Pastick, Katelyn A; Skipper, Caleb P; Pullen, Matthew F; Nicol, Melanie R; Bold, Tyler D; Bangdiwala, Ananta S; Engen, Nicole W; Collins, Lindsey; Williams, Darlisha A; Axelrod, Margaret L; Thielen, Beth K; Hullsiek, Kathy H; Boulware, David R; Rajasingham, Radha
title: Feasibility of SARS-CoV-2 Antibody Testing in Remote Outpatient Trials
date: 2021-10-06
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofab506
sha: 5bc61bc2c3e0120c45109ef88fa1e2295edd571f
doc_id: 1024967
cord_uid: 0lvv7knv

BACKGROUND: During the Covid-19 pandemic, clinical trials necessitated rapid testing to be performed remotely. Dried blood spot (DBS) techniques have enabled remote HIV virologic testing globally and more recently, antibody testing as well. We evaluated DBS testing for SARS-CoV-2 antibody testing in outpatients to assess seropositivity. METHODS: In 2020, we conducted three internet-based randomized clinical trials and offered serologic testing via self-collected DBS as a voluntary sub-study. COVID-19 diagnosis was based on CDC case definition with epidemiological link to cases. A minority reported PCR testing at an outside facility. We tested for anti-SARS-CoV-2 immunoglobulin via Antibody Detection by Agglutination-PCR (ADAP) and compared with ELISA. RESULTS: Of 2727 participants in the primary studies, 60% (1648/2727) consented for serology testing; 56% (931/1648) returned a usable DBS sample. Of those asymptomatic, 5% (33/707) had positive ADAP serology. Of participants with a positive PCR, 67% (36/54) had positive SARS-CoV-2 antibodies. None of those who were PCR-positive and asymptomatic were seropositive (0/7). Of 77 specimens tested for concordance via ELISA, 83% (64/77) were concordant. Challenges of completing a remote testing program during a pandemic included sourcing and assembling collection kits, delivery and return of the kits, and troubleshooting testing. Self-collection was successful for >95% of participants. Delays in US mail with possible sample degradation and timing of DBS collection complicated the analysis. CONCLUSION: We found remote antibody testing during a global pandemic feasible although challenging. We identified an association between symptomatic COVID-19 and positive antibody results at similar prevalence to other outpatient cohorts.

Early in the COVID-19 pandemic, the availability of polymerase chain reaction (PCR) testing (the gold standard for diagnosis) was limited in the United States. Supplies were scarce, and symptomatic persons with COVID-19 or high-risk exposures were unable to attend outpatient facilities due to infection control concerns restricting access. As a result, antibody testing was used to identify the spread of SARS-CoV-2. [1] Traditional serology is performed through venipuncture blood collection by trained personnel in a hospital or clinic setting. Thus, often only those with more severe disease are tested in medical settings. Alternatively, serology performed through a finger-prick, and dried blood spot (DBS) or similar technology with dried blood can be self-collected at home. This home-based approach allows for outpatients, often with less severe disease, to be tested. DBS serology is a well-established rapid method used to identify infectious diseases and is the foundation for newborn screening [2] [3] [4] . DBS has been used to detect antibodies against SARS-CoV-2 antigens, and similar methods of at-home blood collection have been used by the National Health System in the United Kingdom for SARS-CoV-2. [5] Serology tests for SARS-CoV-2 measure response to several proteins, including spike (S) and nucleocapsid (NP), the dominant antigens for host immune response. [6, 7] The S1 domain of the spike protein is the outermost domain and contains the receptor-binding domain (RBD) for the ACE2 A c c e p t e d M a n u s c r i p t receptor, which initiates cell entry. [8] Test validation of different SARS-CoV-2 antibody tests has been controversial, particularly with respect to defining a gold standard. [6] Outpatients have been underrepresented in serology studies with disease correlation. [9] To assess the feasibility of using DBS for antibody testing during a pandemic and to better understand the serologic conversion rates in the outpatient population, we performed a serology sub-study for persons with early COVID-19 and those with a high risk of infection enrolled in three COVID-19 clinical trials.

We hypothesized that participants with symptom-compatible COVID-19 infection would have detectable SARS-CoV-2 antibodies by DBS collection and Antibody Detection by Agglutination-PCR (ADAP) analysis. We further hypothesized that participants with mild or asymptomatic illness would have lower seroconversion rates than in participants with severe disease.

We conducted three randomized, double-blind, placebo-controlled trials investigating the use of hydroxychloroquine as prophylaxis or treatment for early COVID-19 disease. [10] [11] [12] Two trials, one investigating hydroxychloroquine as post-exposure prophylaxis, and one investigating hydroxychloroquine as early preemptive treatment, enrolled participants from March 17, 2020 to May 6, 2020; follow-up concluded on May 20, 2020. The third trial investigating the efficacy of hydroxychloroquine as pre-exposure prophylaxis enrolled participants from April 6, 2020 to May 26, 2020; follow-up concluded on July 13, 2020. Details regarding the study protocols and analysis of the primary endpoints can be found at Clinicaltrials.gov (identifiers NCT04308668 and NCT04328467, respectively).

A c c e p t e d M a n u s c r i p t Inclusion criteria for the post-exposure prophylaxis trial required persons to have a known exposure (within the previous four days) to a lab-confirmed SARS-CoV-2 case either as a healthcare worker, a first responder, or a household contact. Individuals were enrolled into the preemptive early treatment trial with COVID-19 symptoms (less than or equal to four days duration) and either lab-confirmed SARS-CoV-2 or high-risk exposure to a known case within 14 days of symptom onset.

The pre-exposure prophylaxis trial inclusion criteria required persons to be high-risk healthcare workers or first responders with ongoing occupational exposure to COVID-19 patients.

Participants were screened and enrolled in the trials if they met the respective inclusion criteria for each study via an internet-based survey using the Research Electronic Data Capture (REDCap) technology. [13] While overall trial participation included persons living in the United States or select Canadian provinces, only participants in the United States were eligible for participation in the serology sub-study. Full details regarding inclusion and exclusion criteria are published. [10] [11] [12] Enrollment and follow-up data were collected via self-report through REDCap. Participants were asked to report COVID-19 exposure and lab-confirmed SARS-CoV-2 results (if available) on follow-up surveys to assess ongoing risk and status. PCR and outside serology test results were self-reported, and not verified by the study. Only a minority of individuals had PCR testing given the limitations of COVID-19 testing in the USA during March-June of 2020. The majority of participants were healthcare workers.

Reported symptoms were adjudicated as probable or possible COVID-19 disease by three independent physicians using the Council of State and Territorial Epidemiologists reporting guidelines. [14] Per this US case definition, Probable COVID-19 cases had A) at least two of the following symptoms: fever (measured or subjective), chills, rigors, myalgia, headache, sore throat, A c c e p t e d M a n u s c r i p t new olfactory and taste disorder(s) or B) at least one of the following symptoms: cough, shortness of breath, or difficulty breathing. Possible cases per our case definition in this and the other parent studies included at least 1 of the following symptoms: fever (measured or subjective), chills, rigors, myalgia, headache, sore throat, loss of smell, and taste disorder(s) and epidemiologic linkage of exposure to a PCR-positive case. [10] [11] [12] Patient Consent Statement:

Before study enrollment, participant comprehension of clinical trial design, purpose, and drug randomization was assessed via an online survey. Informed consent was obtained through electronic signature capture. All Institutional Review Board (IRB) approvals were obtained through the University of Minnesota.

Participants were invited via email to enroll in the serology sub-study to investigate the prevalence of SARS-CoV-2 antibodies, irrespective of clinical trial or study arm randomization. A separate consent was delivered and signed via REDCap. Upon enrollment into the sub-study, participants were mailed DBS collection kits which included: two lancets, a prelabeled Whatman Proteinsaver card, two bandages, alcohol wipes, a zippered plastic bag for storage, a mailing envelope with return postage, and detailed instructions on how to prepare the sample In June 2020, the only assay validated for DBS was the ADAP method. [15] The validation was done using samples from PCR-positive individuals with symptomatic COVID-19 who had not been hospitalized. [16] Our specimens were sent by courier to Enable Biosciences in San Francisco in two batches in July and August 2020. SARS-CoV-2 serologic testing was later validated for DBS via ELISA assay. [17] Antibody Testing of Dried Blood Spots by ADAP Dried blood spots were processed to detect antibodies against SARS-CoV-2 spike protein, S1, as previously described. [15] Briefly, 3mm discs were isolated from the dried blood spots, incubated in an elution buffer at 37⁰C for 90 minutes, and subsequently run through a molecular weight column.

The recovered sample was then used in an ADAP test to detect the presence of and quantify immunoglobulin antibodies against SARS-CoV-2 spike protein. The ADAP system constitutes an antigen-DNA conjugate which, when exposed to its cognate antibody, leads to immune complex formation. [18] A ligation solution containing DNA ligase and the bridging oligonucleotide was added to the newly formed immune complexes and subsequently mixed with PCR master mix. The final product was analyzed by qPCR, producing a cycle threshold value; high DNA quantity equated to high antibody levels while low DNA quantity equated to low antibody levels. S1 spike protein amino acid 1-674 with Fc tag served as the target antigen and was conjugated to a custom oligonucleotide sequence from Integrated DNA Technologies. [15] Samples were run in batches without technical replicates. Each batch contained an internal positive control consisting of a dried blood spot sample A c c e p t e d M a n u s c r i p t with S1 antibodies as well as a negative control consisting of a dried blood spot sample without S1 antibodies present.

To evaluate if hydroxychloroquine affected seropositivity, we compared seropositivity by treatment arm and using the chi-square test.

We calculated the number of days between the development of COVID-compatible symptoms and DBS collection. If a DBS arrived without a date, we imputed the date as two weeks after the date of informed consent. Similarly, we calculated the number of days between the PCR collection and DBS collection.

To evaluate the correlation between seropositivity, we selected individuals with COVIDcompatible illness and compared seropositivity by number of symptoms. We grouped the number of symptoms into 1, 2-3, 4-5, and 6-7 among those with cough, shortness of breath, fever, myalgia, headache, sore throat, and loss of smell.

Enzyme-linked immunosorbent assay (ELISA) for detecting IgG antibodies against SARS-CoV-2 spike protein S1 domain was performed on a subset of DBS to externally validate ADAP results. The Per the manufacturer's instructions, DBS were eluted with sample buffer, transferred to precoated ELISA plate, incubated, and subsequently treated with enzyme conjugate and substrate solution. The plate was read at a wavelength of 450nm. As this was a qualitative analysis, cutoffs were set at: positive ≥ 1.1, borderline ≥ 0.8 to <1.1, and negative <0.8 as established by

Euroimmun. [17] Samples were run in singles, and 10% of samples were randomly selected to be run in duplicates. As evaluated by calculating the coefficient of variance, experimental precision ranged from 0.55% and 17.45%. Raw readout of the calculated ELISA ratio was compared to raw ADAP results and analyzed by simple linear regression with Pearson's correlation coefficient (r) and p-value reported. We also analyzed the ELISA and PCR qualitative results by McNemar test for concordance.

Of 2727 participants in the primary clinical trials, 931 participants (34.1%) enrolled into the serology sub-study and returned a DBS for testing. Of these 931 participants, 266 were enrolled in the post-exposure prophylaxis trial, 123 were enrolled in the preemptive early treatment trial, and 542 were enrolled in the pre-exposure prophylaxis trial ( Table 1 ). The median age of participants in the serology substudy was 43 years. Of those returning a DBS, 54% were women, 84% self-identified as white, and 88% identified as healthcare workers (Supplemental Table 1 ).

We found that the highest rate of seropositivity was among those in the early treatment trial (29%, 36/123), all with mild COVID-19. Antibody seropositivity was 11% (29/266) in participants A c c e p t e d M a n u s c r i p t receiving post-exposure prophylaxis, and 4% (19/542) in participants receiving pre-exposure prophylaxis.

Among participants with symptoms consistent with probable COVID-19, SARS-CoV-2 seropositivity increased with the number of COVID-19 specific symptoms. Nine percent of participants reporting one COVID-19 specific symptom seroconverted compared with 50% of those with 6-7 COVID-19 specific symptoms (n=224) (Figure 1 ).

Of 931 participants with antibody testing, 121 (13%) reported PCR testing. Of the 54 participants with positive PCR results, 67% (n=36) had detectable SARS-COV-2 antibodies. Given the possibility that persons with more recent illness seroconverted after DBS collection, we performed a secondary analysis of those with DBS collection >21 days from PCR positive testing. We found the A c c e p t e d M a n u s c r i p t seropositivity to be similar (64% (28/44) antibody positivity) in those >21 days from PCR testing compared to the whole cohort.

We further explored seropositivity by the duration between PCR and DBS collection and by symptoms. None of the 7 of participants with asymptomatic, PCR-confirmed SARS-CoV-2 infection had a positive antibody via DBS. Thus, among persons symptomatic with COVID-19 and PCR-positive, seropositivity was 72% (34/47) ( Table 2) .

We evaluated the effect of hydroxychloroquine on seropositivity. We compared seropositivity by study as well as combined among all study cohorts. We found no significant association between the use of hydroxychloroquine and SARS-CoV-2 seropositivity (5% [27/497] of those randomized to hydroxychloroquine versus 5% [21/428] randomized to placebo, p=0.72).

Of the 77 participants who had DBS tested via ELISA, 64 (83%) had consistent qualitative results (positive or negative) as by the ADAP assay. ELISA has a borderline category, while ADAP is only positive or negative. By ELISA, four samples were borderline positive, three of which were positive by ADAP (Figure 2) 

Challenges of completing a remote testing program during a pandemic were related to supply chain challenges, delivery via US mail, and securing an appropriate testing method. Given the supply chain issues in 2020, [19] sourcing supplies, especially lancets, was difficult. Also, troubleshooting lancet size was more difficult than initially anticipated: the smallest lancet possible is preferred for participant comfort, but this must be balanced against obtaining enough blood for the sample to be usable. Given limited funding, the investigators assembled the DBS collection kits.

We created a set of instructions for self-collection. Some individuals continued to have challenges collecting DBS. As an additional reference tool, we created an instructional video that was distributed online to participants (available in supplementary materials). Over 95% of individuals who tried to submit a sample were successful. We used the United States Postal Service in order to limit costs of collection. Unfortunately, there were extensive delays in the postal service during 2020. [20] These delays in mail resulted in lost kits and samples, which were returned after the July cutoff. The longest time frame for a misdelivered kit with return to sender was 9 months. These delays in mail delivery may have contributed to sample degradation in several instances. One of the biggest challenges was ensuring appropriate testing. We initially attempted to run assays internally; however, we determined the ADAP method to be more appropriate, requiring outsourcing of the testing. Further transport time may have also affected results.

A c c e p t e d M a n u s c r i p t

Here we present antibody results from three internet-based, outpatient randomized trials of individuals with early COVID-19 or those at high risk of SARS-CoV-2 infection. We found a seropositivity rate of 28% among those with probable COVID-19 symptoms, 0% among those with possible COVID-19 symptoms, and 5% among those without COVID-19 specific symptoms. specimens approximately 16-20 days after exposure. [21] Our prevalence of COVID-19 antibodies among PCR-positive participants was 67%. This seroprevalence is below previously published surveys of hospitalized patients (80-100% in China). [22, 23] However, several recent studies have shown that antibody production varies significantly by disease severity; outpatients and those with asymptomatic disease having lower antibody conversion and decreased duration of detectable antibodies. [23] [24] [25] [26] Additionally, some data suggest that persons with asymptomatic carriage and positive SARS-CoV-2 PCR have low seroconversion rates. [27] The seroprevalence of our sample of mostly healthcare workers is similar to other surveys of high-risk healthcare workers. A sample of healthcare workers in New York City from April 20, 2020, to June 23, 2020 (during the height of their local incidence) demonstrated a seroprevalence of 14%. [28] A multi-center study reporting data from 13 centers across the USA showed an overall prevalence of 6%,[29] which is similar to our rate among high-risk healthcare workers of 4%.

The lack of a clear 'gold standard' for evaluating serologic testing in COVID-19 remains challenging. Some studies recommend using PCR as the gold standard. [6] However, as previously A c c e p t e d M a n u s c r i p t discussed, PCR correlation with antibody seroprevalence is highly dependent on disease severity and timing of measurement. PCR results were only available from a subset of our participants, given the limited availability of PCR in March to June of 2020, further limiting the utility of this comparison.

ELISA assays have been in general use longer than the ADAP assay; however, both were validated using samples from participants with PCR-confirmed COVID-19 with high sensitivity and specificity. [17, 18] Of note, the ADAP assay validation used outpatient samples, [15] while the ELISA used waste samples from a hospital system. [17] The ADAP and ELISA techniques have not otherwise been compared directly, and neither is known to be superior. Further work is needed to establish a clear diagnostic gold standard, and the current lack thereof remains a limitation in interpreting our results.

DBS may alter the sensitivity of the COVID-19 antibody test as there is a large amount of debris that can interfere with the signal, although DBS-based methods have been validated for similar use cases. [15] Other studies using DBS samples showed a high seroprevalence of COVID-19, [30] and our seropositivity is similar to other studies among high-risk healthcare workers, [28, 29] which suggests the difference is not from assay variations resulting from using DBS. Our lower prevalence is more likely because of low disease severity or asymptomatic carriage, variable time from disease, and DBS collection issues. [27] Finally, we found that that a remote lab-based testing program with DBS was feasible, although challenging. Pragmatic needs like rapid testing across the country must be weighed against quality control issues. While the kits utilized in our study were suitable, Mitra® Specimen Collection Kits were used for some pharmacokinetic studies, although more expensive, required minimal labor to assemble and may be a more appropriate option when considering future remote serologic testing.

A c c e p t e d M a n u s c r i p t

We enrolled the parent studies early in the pandemic via internet-based randomized controlled trials. As such, our testing was performed using self-collected DBS, and there was no validation with fresh plasma samples given the constraints of the pandemic at the time and nature of our trials. The ADAP assay is a relatively new technology, and the assay only targeted the spike protein, which may underrepresent the seroprevalence. However, unlike other tests, they validated the assay in outpatients. At the time, FDA had no regulation regarding antibody tests. All symptoms and PCR results were from self-reported, and while we have confidence in our sample of mostly healthcare workers, we cannot independently verify their results.

We tested COVID-19 antibodies using DBS from 931 clinical trial participants with PCRconfirmed COVID-19 or COVID-19 compatible symptoms, in addition to individuals at high risk for SARS-CoV-2 infection during the first wave of the pandemic. We found that SARS-CoV-2 seropositivity is correlated with symptom severity, with increasing seropositivity with increasing number and severity of symptoms. The percent seropositivity is lower than prior inpatient studies but consistent with previous outpatient studies.

DBS sampling is potentially a feasible method to perform remote lab testing in internetbased clinical trials. However, further work is needed in the serologic testing field to establish a gold standard and test outpatient samples. New assays specific for outpatients or those with asymptomatic carriage would be helpful for future work.

A c c e p t e d M a n u s c r i p t

We would like to thank our participants for enrolling in the main trials and this sub-study. We could not do this work without you.

Serology testing in the COVID-19 pandemic response

Evaluation of a dried blood spot HIV-1 RNA program for early infant diagnosis and viral load monitoring at rural and remote healthcare facilities

Current and future applications of dried blood spots in viral disease management

The Current State of Newborn Screening in the United States

Sensitive Detection of SARS-CoV-2-Specific Antibodies in Dried Blood Spot Samples

Measuring the Serologic Response to Severe Acute Respiratory Syndrome Coronavirus 2: Methods and Meaning

The trinity of COVID-19: immunity, inflammation and intervention

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Test performance evaluation of SARS-CoV-2 serological assays. medRxiv 2020

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

Hydroxychloroquine as Preexposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial

Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial

Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support

Interim-20-ID-01: Standardized surveillance case definition and national notification for 2019 novel coronavirus disease (COVID-19)

A serological assay to detect SARS-CoV-2 antibodies in at-home collected finger-prick dried blood spots

Question about your validation study

Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies

Ultrasensitive Antibody Detection by Agglutination-PCR (ADAP)

Global Supply Chains in a Post-Pandemic World

Revealed: evidence shows huge mail slowdowns after Trump ally took over. The Guardian

A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19

A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients

Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients

SARS-CoV-2 Antibody Responses Correlate with Resolution of RNAemia But Are Short-Lived in Patients with Mild Illness

SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease

Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation

Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients

Prevalence of SARS-CoV-2 Antibodies in Health Care Personnel in the New York City Area

Among Frontline Health Care Personnel in a Multistate Hospital Network-13

High seroprevalence for SARS-CoV-2 among household members of essential workers detected using a dried blood spot assay

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t